Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51422
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12642]
Metadata
Show full item record
TARGETING MICROBIOME: AN ALTERNATIVE STRATEGY FOR FIGHTING SARS-COV-2 INFECTION
Disbiose
Eixo intestino-pulmão
Probióticos
Tempestade Sistêmica de Citocinas
Microbioma
SARS-CoV-2
COVID-19
Gut-lung axis
Probiotics
Systemic cytokine storm
SARS-CoV-2
Targeting Microbiome
Author
Affilliation
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas, Laboratório de Genética Celular e Molecular. Belo Horizonte, MG, Brasil.
Unit of Clinical Laboratory Science, University of Biomedical Campus. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy / Migrant and Global Health Research Organization (Mi-HeRo), Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas, Laboratório de Genética Celular e Molecular. Belo Horizonte, MG, Brasil.
Unit of Clinical Laboratory Science, University of Biomedical Campus. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Medical Statistic and Molecular Epidemiology Unit. University of Biomedical Campus, Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy / Migrant and Global Health Research Organization (Mi-HeRo), Rome, Italy.
Sapienza University of Rome. Department of Public Health and Infectious Diseases. Rome, Italy / COVID-19 Unit, Azienda Policlinico “Umberto I” University Hospital. Rome, Italy.
Abstract
Respiratory and gastrointestinal symptoms are the predominant
clinical manifestations of the coronavirus disease 2019
(COVID-19). Infecting intestinal epithelial cells, the severe
acute respiratory syndrome coronavirus-2 may impact on
host’s microbiota and gut inflammation. It is well established
that an imbalanced intestinal microbiome can affect pulmonary
function, modulating the host immune response (“gutlung
axis”). While effective vaccines and targeted drugs are
being tested, alternative pathophysiology-based options to
prevent and treat COVID-19 infection must be considered on
top of the limited evidence-based therapy currently available.
Addressing intestinal dysbiosis with a probiotic supplement
may, therefore, be a sensible option to be evaluated,
in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration
in preventing and treating COVID-19 pneumonia.
Keywords in Portuguese
COVID-19Disbiose
Eixo intestino-pulmão
Probióticos
Tempestade Sistêmica de Citocinas
Microbioma
SARS-CoV-2
Keywords
DysbiosisCOVID-19
Gut-lung axis
Probiotics
Systemic cytokine storm
SARS-CoV-2
Targeting Microbiome
Share